KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) EBITDA Margin (2016 - 2025)

Eli Lilly's EBITDA Margin history spans 17 years, with the latest figure at 46.15% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 671.0% year-over-year to 46.15%; the TTM value through Dec 2025 reached 44.82%, up 890.0%, while the annual FY2025 figure was 44.82%, 890.0% up from the prior year.
  • EBITDA Margin reached 46.15% in Q4 2025 per LLY's latest filing, up from 45.57% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 46.15% in Q4 2025 to a low of 21.46% in Q2 2021.
  • Average EBITDA Margin over 5 years is 32.62%, with a median of 31.29% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -993bps in 2023, then skyrocketed 1150bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 29.44% in 2021, then decreased by -3bps to 28.44% in 2022, then rose by 13bps to 32.18% in 2023, then rose by 23bps to 39.44% in 2024, then increased by 17bps to 46.15% in 2025.
  • Per Business Quant, the three most recent readings for LLY's EBITDA Margin are 46.15% (Q4 2025), 45.57% (Q3 2025), and 45.13% (Q2 2025).